title: My treatment approach to the management of ulcerative colitis.
abstract: Ulcerative colitis diagnosis and management represent a challenge for clinicians. The disguises of ischemia and acute infectious colitis continue to confound the diagnosis. The therapeutic options have remarkably expanded in the way of immunomodulators, biologics, or ileoanal pouch surgery, yet all carry potential considerable risks. These risks can confuse and impair patient acceptance, particularly elderly patients and men younger than 30 years. Predictors of outcome of medical and surgical therapy have improved but are far from complete. Nevertheless, therapies focused on the specific patient's condition continue to offer hope.
authors.affiliation: Department of Medicine, New York University School of Medicine, New York, NY; North Shore University Hospital-Long Island Jewish Health System, Manhasset, NY; and St Francis Hospital, Roslyn, NY. Electronic address: Seymourkatz.md@gmail.com.
authors.forename: Seymour
authors.initials: S
authors.lastname: Katz
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003082:Colectomy / Q000379:methods*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000191:economics / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D019468:Disease Management; D016527:Drug Costs; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D062072:Patient Acuity; D017410:Practice Guidelines as Topic; D019936:Probiotics / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012812:Sigmoidoscopy / Q000379:methods; D061665:Time-to-Treatment
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D019804:Mesalamine; D000069285:Infliximab
keywords: BMS; C-reactive protein; CBC; CMV; CRP; FCP; GETAID; Groupe d'Etude Thérapeutique des Affections Inflammatories du Tube Digestif; IBD; PIANO; Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes; TNF; TPMT; UC; bowel movements; complete blood cell; cytomegalovirus; fecal calprotectin; irritable bowel disease; thiopurine methyltransferase; tumor necrosis factor; ulcerative colitis